Guangzhou Cellprotek Pharmaceutical Co., Ltd

Hon Hai Precision Industry Co., Ltd.

Premier Image Technology (china) Ltd.

Guangzhou Virotech Pharmaceutical Co., Ltd.

Hongfujin Precision Industry (wuhan) Co., Ltd.

Sun-bio Medical Device Co., Ltd.

Wei Yin

Guangmei Yan

Bingzheng Lu

Suizhen Lin

Wenbo Zhu

Yijun Huang

Longxiang Sheng

Jun Hu

Jingxia Zhang

Kai Li

Yuan Li

Pengxin Qiu

Haiyan Hu

Haipeng Zhang

Yuan Lin

Xiao Xiao

Jiankai Liang

Jiesi Chen

Shoufang Gong

Yaqian Tan

Jing Cai

Yun-Lung Chen

Hong Li

Yu-Ming Xiao

Liang-Chin Wang

Zi-Yuan Li

Yang-Cheng Luo

Provided are applications of a hexokinase 2-specific inhibitor in preparing a medicament for preventing and treating acute central nervous system injury.

Hexokinase 2-specific inhibitors for use in acute central nervous system injury

Disclosed is use of 5α-androst-3β,5,6β-triol or an analogue, a deuterated compound or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cerebral small vessel disease in a patient. The cerebral small vessel disease is preferably cerebral microbleed. The cerebral microbleed is spontaneous cerebral microbleed, drug-related cerebral microbleed, or traumatic cerebral microbleed. The present invention demonstrates that these compounds significantly enhance the clearance of extravascular hemoglobin, and thus can be used to treat cerebral small vessel disease.

Use of compound in preparation of drug for treating cerebral small vessel disease

Disclosed is a use of 5&#x3b1;-androstane-3&#x3b2;,5,6&#x3b2;-triol, an analogue, a deuterated derivative, and a pharmaceutically acceptable salt thereof in manufacture of a medicament for the treatment of hemorrhagic stroke in a patient. The hemorrhagic stroke is intracerebral hemorrhage or subarachnoid hemorrhage.

Use of compounds in preparation of a medicament for treatment of hemorrhagic stroke

The present invention belongs to the field of biomedicine and relates to use of VCP (valosin-containing protein, VCP) inhibitor and oncolytic virus in the preparation of an anti-tumor drug. The present invention firstly discovers that VCP inhibitor can be used in the preparation of an anti-tumor synergist for oncolytic virus. Meanwhile, the present invention relates to a pharmaceutical composition comprising VCP inhibitor and oncolytic virus, a pharmaceutical kit comprising VCP inhibitor and oncolytic virus, and use of VCP inhibitor and oncolytic virus for treating tumor, especially a tumor that is not sensitive to oncolytic virus. The present invention also relates to an anti-tumor administration system, characterized in that, comprising oncolytic virus and a reagent for detecting the expression level of VCP.

Use of VCP inhibitor and oncolytic virus in the preparation of an anti-tumor drug

Described herein is use of a Caspase activator and an oncolytic virus in the preparation of an anti-tumor drug. As described, Caspase activator can enhance the anti-tumor effect of oncolytic virus, and the combination of Caspase activator and oncolytic virus produces a significant synergistic anti-tumor effect, and demonstrates an effective therapy for the treatment of tumors that are less sensitive to other pharmaceutical treatments.

Use of IAP inhibitor and oncolytic virus in preparation of anti-tumor drug

A bispecific antibody that simultaneously targets humanized p185 and VEGF, consisting of the four peptide chains: two identical antibody light chains that are the light chains of the antibody that identify the epitope or antigen of p185, and two identical antibody heavy chains that have the amino acid sequence of a recombinant antibody from N- to C-terminus, a light chain sequence of the antibody that recognizes the p185 epitope or the antigen; a constant heavy chain region; a flexible short peptide sequence; and either a single-stranded variable region sequence (ScFv) of anti-VEGF antibody which recognizes the VEGF epitope or antigen, or a receptor domain sequence that binds to VEGF. The bispecific antibody has the ability to bind p185 and VEGF at the same time, inhibits the proliferation of tumor cells, and promotes the expression of IFN-&#x3b3; by T lymphocytes; it may be applied as anti-tumor antibody drug.

Bispecific antibody targeting human p185 and vascular endothelial growth factor and application thereof

Use of 5&#x3b1;-androstane-3&#x3b2;,5,6&#x3b2;-triol and analogs thereof in the preparation of a drug for the prophylaxis or treatment of an altitude sickness caused by hypobaric hypoxia is provided, so as to provide a new drug for the prophylaxis or treatment of an altitude sickness. Researches revealed that 5&#x3b1;-androstane-3&#x3b2;,5,6&#x3b2;-triol treatment can effectively reduce vasogenic edema of brain tissue ofcaused by hypobaric hypoxia, reduce the increased cerebral water content, and protect from neuronal vacuolar degeneration caused by hypobaric hypoxia, therefore it can improve neurological dysfunctions caused by hypobaric hypoxia and is useful in prophylaxis or treatment of an altitude sickness.

Neuro-protective agents and uses thereof

A computer case includes a main body and a sidewall assembled to the main body. The main body includes a bottom plate and two side plates extending upwardly from two opposite edges of the bottom plate. Each side plate includes a positioning portion, and a latching part defined on the positioning portion. The side plate adjacent to the latching part also includes a sliding groove. The latching part and the sliding groove are used for securing different kinds of side plates respectively.

Computer case

Provided is a lens module for imaging an object on an image plane. In the order from the object side to the image side of the lens module, the lens module includes a first lens made of glass and having positive refraction power, a second lens made of plastic and having negative refraction power, a aperture stopper, a third lens having positive refraction power, and a fourth lens having negative refraction power. The lens module satisfies the following formula: Vd&#x2212;Vd&#x2267;35; wherein, Vdis the Abbe number of the first lens in d light and Vdis the Abbe number of the second lens in the d light.

Lens module with low chromatic aberration

A wide-conversion lens, in order from the object-side to the image-side, includes a first lens with negative refraction power, a second lens with negative refraction power, a third lens with positive refraction power, a fourth lens with positive refraction power, and a fifth lens with negative refraction power. The first lens includes a surface facing the object side. The wide-conversion lens satisfies the following conditions: R1&#x3c;0; V&#x2212;V&#x2267;19; V&#x2212;V&#x2267;35. Wherein, R1 is the curvature radius of the surface of the first lens; Vis the Abbe number of the first lens; Vis the Abbe number of the second lens; Vis the Abbe number of the third lens.

Wide-conversion lens

Growing community of inventors

Guangdong, China

Wei Yin